In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?
Bacteria belonging to the genus <i>Achromobacter</i> are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international recommendations, therapeutic guideli...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/9/12/2473 |
| _version_ | 1797502380912148480 |
|---|---|
| author | Clémence Beauruelle Claudie Lamoureux Arsid Mashi Sophie Ramel Jean Le Bihan Thomas Ropars Anne Dirou Anandadev Banerjee Didier Tandé Hervé Le Bars Geneviève Héry-Arnaud |
| author_facet | Clémence Beauruelle Claudie Lamoureux Arsid Mashi Sophie Ramel Jean Le Bihan Thomas Ropars Anne Dirou Anandadev Banerjee Didier Tandé Hervé Le Bars Geneviève Héry-Arnaud |
| author_sort | Clémence Beauruelle |
| collection | DOAJ |
| description | Bacteria belonging to the genus <i>Achromobacter</i> are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international recommendations, therapeutic guidelines and data concerning antibiotic susceptibility, especially concerning the newer antibiotics. The objective of this study was to describe the antibiotic susceptibility of <i>Achromobacter</i> isolates from PWCF, including susceptibility to new antibiotics. The minimum inhibitory concentrations (MICs) of 22 antibiotics were determined for a panel of 23 <i>Achromobacter</i> isolates from 19 respiratory samples of PWCF. Two microdilution MIC plates were used: EUMDROXF<sup>®</sup> plate (Sensititre) and Micronaut-S Pseudomonas MIC<sup>®</sup> plate (Merlin) and completed by a third method if necessary (E-test<sup>®</sup> or UMIC<sup>®</sup>). Among usual antimicrobial agents, the most active was imipenem (70% susceptibility). Trimethoprim-sulfamethoxazole, piperacillin and tigecycline (65%, 56% and 52% susceptibility, respectively) were still useful for the treatment of <i>Achromobacter</i> infections. Among new therapeutic options, β-lactams combined with a β-lactamase-inhibitor did not bring benefits compared to β-lactam alone. On the other hand, cefiderocol appeared as a promising therapeutic alternative for managing <i>Achromobacter</i> infections in PWCF. This study provides the first results on the susceptibility of clinical <i>Achromobacter</i> isolates concerning new antibiotics. More microbiological and clinical data are required to establish the optimal treatment of <i>Achromobacter</i> infections. |
| first_indexed | 2024-03-10T03:32:17Z |
| format | Article |
| id | doaj.art-5e97949813564c3eb3f06f339a791c3a |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-10T03:32:17Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-5e97949813564c3eb3f06f339a791c3a2023-11-23T09:38:30ZengMDPI AGMicroorganisms2076-26072021-11-01912247310.3390/microorganisms9122473In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options?Clémence Beauruelle0Claudie Lamoureux1Arsid Mashi2Sophie Ramel3Jean Le Bihan4Thomas Ropars5Anne Dirou6Anandadev Banerjee7Didier Tandé8Hervé Le Bars9Geneviève Héry-Arnaud10University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, FranceUniversity Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, FranceDepartment of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, FranceCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Presqu’île de Perharidy, 29680 Roscoff, FranceCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Presqu’île de Perharidy, 29680 Roscoff, FranceCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Presqu’île de Perharidy, 29680 Roscoff, FranceCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Presqu’île de Perharidy, 29680 Roscoff, FranceCentre de Ressources et de Compétences de la Mucoviscidose, Fondation Ildys, Presqu’île de Perharidy, 29680 Roscoff, FranceDepartment of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, FranceDepartment of Bacteriology, Virology, Hospital Hygiene, and Parasitology-Mycology, Brest University Hospital, 29200 Brest, FranceUniversity Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, FranceBacteria belonging to the genus <i>Achromobacter</i> are increasingly isolated from respiratory samples of people with cystic fibrosis (PWCF). The management of this multidrug-resistant genus is challenging and characterised by a lack of international recommendations, therapeutic guidelines and data concerning antibiotic susceptibility, especially concerning the newer antibiotics. The objective of this study was to describe the antibiotic susceptibility of <i>Achromobacter</i> isolates from PWCF, including susceptibility to new antibiotics. The minimum inhibitory concentrations (MICs) of 22 antibiotics were determined for a panel of 23 <i>Achromobacter</i> isolates from 19 respiratory samples of PWCF. Two microdilution MIC plates were used: EUMDROXF<sup>®</sup> plate (Sensititre) and Micronaut-S Pseudomonas MIC<sup>®</sup> plate (Merlin) and completed by a third method if necessary (E-test<sup>®</sup> or UMIC<sup>®</sup>). Among usual antimicrobial agents, the most active was imipenem (70% susceptibility). Trimethoprim-sulfamethoxazole, piperacillin and tigecycline (65%, 56% and 52% susceptibility, respectively) were still useful for the treatment of <i>Achromobacter</i> infections. Among new therapeutic options, β-lactams combined with a β-lactamase-inhibitor did not bring benefits compared to β-lactam alone. On the other hand, cefiderocol appeared as a promising therapeutic alternative for managing <i>Achromobacter</i> infections in PWCF. This study provides the first results on the susceptibility of clinical <i>Achromobacter</i> isolates concerning new antibiotics. More microbiological and clinical data are required to establish the optimal treatment of <i>Achromobacter</i> infections.https://www.mdpi.com/2076-2607/9/12/2473<i>Achromobacter</i>non-fermenting Gram-negative bacillicystic fibrosisantibiotic susceptibilityresistancemultidrug resistance |
| spellingShingle | Clémence Beauruelle Claudie Lamoureux Arsid Mashi Sophie Ramel Jean Le Bihan Thomas Ropars Anne Dirou Anandadev Banerjee Didier Tandé Hervé Le Bars Geneviève Héry-Arnaud In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? Microorganisms <i>Achromobacter</i> non-fermenting Gram-negative bacilli cystic fibrosis antibiotic susceptibility resistance multidrug resistance |
| title | In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? |
| title_full | In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? |
| title_fullStr | In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? |
| title_full_unstemmed | In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? |
| title_short | In Vitro Activity of 22 Antibiotics against <i>Achromobacter</i> Isolates from People with Cystic Fibrosis. Are There New Therapeutic Options? |
| title_sort | in vitro activity of 22 antibiotics against i achromobacter i isolates from people with cystic fibrosis are there new therapeutic options |
| topic | <i>Achromobacter</i> non-fermenting Gram-negative bacilli cystic fibrosis antibiotic susceptibility resistance multidrug resistance |
| url | https://www.mdpi.com/2076-2607/9/12/2473 |
| work_keys_str_mv | AT clemencebeauruelle invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT claudielamoureux invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT arsidmashi invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT sophieramel invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT jeanlebihan invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT thomasropars invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT annedirou invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT anandadevbanerjee invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT didiertande invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT hervelebars invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions AT genevieveheryarnaud invitroactivityof22antibioticsagainstiachromobacteriisolatesfrompeoplewithcysticfibrosisaretherenewtherapeuticoptions |